Arbutus Biopharma (ABUS) Common Equity (2009 - 2026)

Arbutus Biopharma's Common Equity history runs 18 years deep, the most recent figure standing at $260.2 million for Q1 2026.

• In Q1 2026, Common Equity rose 228.68% year-over-year to $260.2 million; the TTM figure through Mar 2026 stood at $260.2 million (up 228.68% YoY), while the FY2025 annual figure was $76.6 million, down 21.35% from the prior year.
• Common Equity came in at $260.2 million for Q1 2026 at Arbutus Biopharma, up from $76.6 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $260.2 million in Q1 2026 to a low of $76.6 million in Q4 2025.
• A 5-year average of $124.9 million and a median of $119.3 million in 2023 frame the typical range for Common Equity.
• Across the five-year window, Common Equity slumped 32.24% in 2025 and jumped 228.68% in 2026, its largest moves.
• Arbutus Biopharma's Common Equity stood at $136.9 million in 2022, then decreased by 22.53% to $106.0 million in 2023, then retreated by 8.16% to $97.4 million in 2024, then dropped by 21.35% to $76.6 million in 2025, then jumped by 239.76% to $260.2 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $260.2 million, $76.6 million, and $77.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison